Vibrio Parahaemolyticus Infection

The vaccine and therapy creation process for Vibrio parahaemolyticus is an evolving and difficult endeavor. By leveraging the latest scientific insights and technological advancements, we are committed to providing robust solutions that address the complexities of this foodborne pathogen.

Overview of Vibrio Parahaemolyticus Infection

Vibrio parahaemolyticus is a salt-loving organism that is primarily present in marine habitats and is considered to be an important cause of gastroenteritis which is present in s seafood. This pathogen infected people are usually associated with eating raw/undercooked meats and shell. V. parahaemolyticus infection diagnostics are base on diarrhea, abdominal pain, and nausea accompanied by vomiting which in most of the cases goes away without medical treatment however, in some instances might have serious effects. Its danger is compounded by the increase in multidrug-resistant strains which pose a considerable burden on public health. The development of appropriate vaccines and therapies is intensely required.

Fig.1 Regulatory analysis of the T3SS1 gene in Vibrio parahaemolyticus. (Li L., et al., 2019)

Vaccine Development for Vibrio Parahaemolyticus Infection

Subunit Vaccines

Recent studies have achieved success in isolating hyper-antigenic epitopes on the V. parahaemolyticus proteins which have resulted in candidate subunit vaccines. For example, such constructs as V1, V2, and V3 have been created by fusing such epitopes with appropriate adjuvants in order to improve immunogenicity.

Inactivated Vaccines

Though currently unavailable in the market, inactivated or killed vaccines have been used to treat other Vibrio species. There is an active investigation on the use of the inactivated V. parahaemolyticus but the focus remains on the safe and effective use of the vaccine. The difficulty is developing a formulation capable of conferring protection against different strains of the bacterium.

Therapeutics Development for Vibrio Parahaemolyticus Infection

Antibiotics

In the past, first-line therapeutics would include the use of antibiotics such as tetracycline and fluoroquinolones. But thanks to the antibiotic resistance development, new antimicrobial agents have been sought.

Alternative Biocontrol Agents

Considering the concern regarding the increasing antibiotic resistance, there is an interest in the alternative approaches including the use of bacteriophages, antimicrobial peptides and other antimicrobial natural compounds.

Immunotherapies

Immunotherapy employs targeting the immune effort against V. parahaemolyticus, growing the immune response which translates to more precise therapeutics methods.

Our Services

Our company has experience in developing vaccines and therapies against infections caused by Vibrio parahaemolyticus, with a commitment to service covers all aspects of the development process. Our highly skilled team of experts implements the latest technologies and approaches to therapeutically target and optimize the new agents and vaccine candidates.

Vaccine Development

• Live-attenuated Vaccine
• Inactivated Vaccine
• Toxoid Vaccine
• Viral Vector Vaccine
• Virus-like Particles Vaccine
• Protein Subunit Vaccine
• mRNA Vaccine
• DNA Vaccine

Therapeutic Development

• Small Molecule Drug Development Services
• Therapeutic mRNA Development Services
• Therapeutic Antibody Development Services
• Cell Therapy Development Services

Disease Models

• Rabbit Ligated Ileal Loop Models
• Orogastric Inoculation of Piglets and Infant Rabbits
• Streptomycin-Pretreated Mouse Models
• Zebrafish (Danio rerio) Models

We offer expertise in antigen identification, vaccine construct design, and preclinical research, ensuring that our clients receive scientifically robust and clinically relevant solutions. If you are interested in our services, please feel free to contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.